| Title: |
NEPTUNE: Phase III study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC |
| Authors: |
de Castro, G., Jr.; Rizvi, N. A.; Schmid, P.; Syrigos, K.; Martin, C.; Yamamoto, N.; Cheng, Y.; Moiseyenko, V.; Summers, Yvonne J; Vynnychenko, I.; Lee, S. Y.; Bryl, M.; Zer, A.; Erman, M.; Timcheva, C.; Raja, R.; Naicker, K.; Scheuring, U.; Walker, J.; Mann, H.; Chand, V.; Mok, T. |
| Contributors: |
Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil. |
| Publication Year: |
2022 |
| Collection: |
The Christie School of Oncology: Christie Research Publications Repository |
| Description: |
Introduction: NEPTUNE, a phase III, open-label study, evaluated first-line durvalumab plus tremelimumab versus chemotherapy in metastatic NSCLC (mNSCLC). Methods: Eligible patients with EGFR/ALK wild-type mNSCLC were randomized (1:1) to first-line durvalumab (20 mg/kg q4w until progression) plus tremelimumab (1 mg/kg q4w for up to 4 doses) or standard chemotherapy. Randomization was stratified by tumor PD-L1 expression (≥25% vs |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://dx.doi.org/10.1016/j.jtho.2022.09.223; http://hdl.handle.net/10541/625720; Journal of Thoracic Oncology |
| DOI: |
10.1016/j.jtho.2022.09.223 |
| Availability: |
http://hdl.handle.net/10541/625720; https://doi.org/10.1016/j.jtho.2022.09.223 |
| Accession Number: |
edsbas.E512D0A0 |
| Database: |
BASE |